Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 24;24(3):2312. doi: 10.3390/ijms24032312

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

The mechanism of pralsetinib, selpercatinib, cabozantinib, and vandetanib inhibiting different receptors and their respective intracellular cascades. Only receptors inhibited by cabozantinib being investigated in the EXAM study are mentioned. RET: Rearranged during transfection. MET: Tyrosine-protein kinase met or hepatocyte growth factor receptor. VEGFR-2: Vascular epithelial growth factor 2. EFGR: Epidermal growth factor receptor. RAS: Rat sarcoma. RAF: Rapidly accelerated fibrosarcoma. MEK: Mitogen-activated protein kinase kinase-1. ERK: Extracellular regulated kinase. MAPK: Mitogen-activated protein kinase. PI3K: Phosphoinositide 3 kinases. AKT: Protein kinase B. mTOR: Mammalian target of rapamycin. MDM2: Mouse double minute 2. BAD: BCL2 associated agonist of cell death. The figure was created in Miro.